Most tried versus what happened
Rifaximin dominates the dataset, but its outcomes are still divided.
Rifaximin / Xifaxan appears in 1,113 stories—about 1.9 times as many as Low FODMAP diet, the next most-reported treatment at 578 stories. Frequency shows what people commonly try; it does not establish consistent success.
For Rifaximin / Xifaxan, 22% reported it helped and 22% reported partial help, while 49% reported no change and 7% reported being made worse. That mixed distribution is more useful than a yes-or-no claim about whether rifaximin “works.”
Low FODMAP diet has a 55% combined helped-or-partially-helped share across 578 stories, while 42% reported no change and 3% reported being made worse. In these stories it is usually described as symptom management; the outcomes do not show that it treats an underlying cause or support long-term restriction.
Proton pump inhibitor (PPI) provides a useful contrast: only 27% reported full or partial help, while 48% reported no change and 25% reported being made worse.